Afamelanotide in fair-skinned Parkinson’s patients
CLINUVEL PHARMS LTD S/ADR (CLVLY)
NASDAQ:AMEX Investor Relations:
clinuvel.com/investors
Company Research
Source: GlobeNewswire
MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or Parkinson’s) in fair-skinned patients. The program objectives are to determine whether afamelanotide – through melanocortin-1 receptor (MC1R) activation – is able to lower a-synuclein (a toxin) in blood levels in PD patients, and positively affect neurons of the midbrain. MC1R is known to be a key receptor in brain and skin cells. In large studies, it was found that fair-skinned patients have a higher risk of PD associated with a malfunctioning MC1R.a, 1-2 Since afamelanotide is known to optimise the function of the MC1R, it is hypothesised that the drug treatment would have a positive effect in PD by lowering a-synuclein, as recently demonstrated in preclinical studies.²¯³ Afamelanotide is marketed in Europe and the USA as SCENESSE® for patients diagnosed with erythropoietic protoporphyria (EPP
Show less
Read more
Impact Snapshot
Event Time:
CLVLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLVLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLVLY alerts
High impacting CLINUVEL PHARMS LTD S/ADR news events
Weekly update
A roundup of the hottest topics
CLVLY
News
- 3 ASX Growth Companies With Insider Ownership Up To 22% [Yahoo! Finance]Yahoo! Finance
- High Growth Tech Stocks to Watch in Australia September 2024 [Yahoo! Finance]Yahoo! Finance
- ASX Growth Stocks With Insider Ownership Up To 33% [Yahoo! Finance]Yahoo! Finance
- 3 ASX Growth Stocks With At Least 11% Insider Ownership [Yahoo! Finance]Yahoo! Finance
- High Growth Tech Stocks in Australia Featuring These 3 Promising Companies [Yahoo! Finance]Yahoo! Finance